Important research results focus on new advances in the field of peptide drug molecular research!

!-- webeditor: page title"--In this article, the small compilation of a number of important research results, together focus on scientists in the field of peptide drug molecular research new progress, share to everyone! Photo credit: Science Translational Medicine, 2020, doi: 10.1126/scitranslmed.aaz7287 (Science Sub-journal: Using M3mP6 polypeptide high-load nanoparticles is expected to treat heart disease doi: 10.1126/sci In a new study, researchers at the University of Illinois at Chicago have developed a new drug that prevents blood clots and does not increase the risk of bleeding, a common side effect of all platelet drugs.related findings published in the journal Science Translational Medicine.the new study describes the drug and its delivery mechanism, and says it is also an effective treatment for heart disease in animal models. "Unfortunately, current antiplatelet drugs prevent the formation of blood clots that lead to heart disease and stroke, but if blood vessels break, they can also disrupt platelet's hemorrhage,"Du said.in some cases, severe bleeding can be life-threatening.the magic of the new drug is that it prevents blood clots, but it doesn't make people bleed easily, but other drugs can't.":Chem Commun: New peptide molecules can be used to treat gastrointestinal disorders doi: 10.1039/D0CC02321TFF1 peptides are key players in mucous membrane protection and repair.in a recent study, the team led by Markus Muttenthaler of the Department of Chemistry at the University of Vienna successfully synthesized and folded TFF1 peptides for the first time.three known trefoil family peptides TFF1, TFF2 and TFF3 are mainly produced by the gastrointestinal mucosa.named after its three-leaf folding structure.studies have shown that these peptides, which are the product of local resistance to inflammation and gastrointestinal damage by accelerating wound healing, have great potential for treating gastrointestinal and other mucosa diseases such as dry eye disease and asthma. "So far, there are two oral peptide treatments on the market for diseases such as irritable bowel syndrome," saidMuttenthaler.Because the molecules are relatively large in size, they are not absorbed into the blood stream through the gastrointestinal wall, so they can only function locally in the gastrointestinal tract without serious side effects." scientists have developed a new type of experimental peptide molecule or can effectively target THE treatment of COVID-19 infection COVID-19 infection News Reading: Experimental peptide targets COVID-19 Recently, scientists from MIT and other institutions have designed a new type of peptide by studying computer models using protein interaction, which can bind coronavirus proteins and break them down through cell pathways, this type of peptide or as a potential treatment to suppress SARS infection.the idea of using a computer technique to engineer peptides to treat COVID-19, which can simply label and degrade viruses once they enter cells.researchers have now tested the new peptide in human cells, and are now planning cell and animal studies to assess their efficacy, the researchers reported in a June 1 issue of bioRxiv, a preprinted platform.scientists are looking for a number of different strategies to develop new treatments for COVID-19, one of which is to develop special antibodies to bind inactive viral proteins, such as stinging proteins, which can be used by coronaviruses to enter human cells; MIT researchers are working on engineering modifications to make polypeptides so that they can bind strongly to the stingproteins inside the cell, while also using these peptides to stimulate cell-crushing viral proteins, and the idea is for peptides to recruit a naturally present protein called E3 ubiquitin connecting enzymes that can be labeled and destroyed when cells no longer need them. : Researchers designed polypeptides to treat COVID-19doi: 10.1021/acsnano.0c02857 Scientists around the world are scrambling to find inhibitors of SARS-CoV-2. SARS-CoV-2 is a new coronavirus that causes the COVID-19 pandemic. now, researchers report on ACS Nano that they have used computer modeling to evaluate four peptides that simulate the viral binding domain of human proteins -- the key proteinthat that allows SARS-CoV-2 to enter cells. to infect cells, SARS-CoV-2 binds its protrusion protein to ACE2 receptors, a protein located on the surface of certain human cells. this attachment fuses the virus into and into the host cell membrane. many researchers have been trying to find compounds that block the key areas of this protrusion protein, thereby preventing the infection of cells. Yanxiao Han and Petr Kral wanted to use computer modeling to design compounds that mimic the natural target of this bulging protein, ACE2. 5) bioRxiv: Breakthrough! Synthetic polypeptide drugs can block the binding of SARS-CoV-2 viruses to human cells: 10.1101/2020.03.19.999318 In order to develop a possible treatment for COVID-19, a group of chemists at the Massachusetts Institute of Technology have devised a candidate drug that they believe can prevent coronaviruses from entering human cells. the potential drug is a short protein fragment, or peptide segment, that mimics a protein found on the surface of human cells. researchers have shown that their new peptides can bind to the viral proteins used by coronaviruses to enter human cells, potentially disarming them. !--/ewebeditor--!--webeditor:page title"--"We have the main compound spent that we really want to explore, because it actually interacts with the virus protein in a way that we predict, so it has a chance to inhibit the virus from entering the host cell," said Brad Pentelute, an associate professor of chemistry at the Massachusetts Institute of Technology, who led the study. MIT team reported their initial findings in a preprint edited version of bioRxiv, an online preprint server, released on March 20. they have sent samples of peptides to partners who plan to test them in human cells. Photo Credit: Bi W, et al. (2019) 6:PLoS Pathog: New engineered peptides or potential long-acting anti-HIV potential doi: 10.1371/journal.ppat.1008082, one In a study published in the international journal PLoS Agency, scientists from Fudan University and others found that a new type of engineered peptide, IBP-CP24, may be used as a long-acting anti-HIV drug that can be used alone or with a wide range of neutral antibodies to treat and prevent HIV-1 infection. the study, the researchers noted that IBP-CP24 can exhibit a longer half-life, while potentially carrying a wide range of anti-HIV-1 activities, even for drug-resistant strains. enfweire is the first FDA-approved anti-HIV peptide drug, however, because of its short half-life and easy to produce drug-resistant HIV strains, the clinical application of this drug is often very limited. this study, researchers developed a new strategy that can extend the half-life of the peptide by fusing short anti-HIV peptides called CP24 into the human immunoglobulin G (IgG) Fc binding peptides (IBPs). . JCI: New Discovery! A special peptide that mimics good cholesterol or is expected to reverse inflammatory bowel disease! Doi: 10.1172/JCI123700 In a recent study published in the international journal Journal of Clinical Science, scientists from the University of California found that a special peptide class may mimic the function of high-density lipoprotein (HDL, a good cholesterol) that may help treat inflammation associated with inflammatory bowel disease (IBD); inflammatory bowel disease is a chronic gastroenteritis disease, the most common inflammatory bowel disease includes Crohn's disease and ulcerative colitis, currently for inflammatory bowel disease almost no effective treatment, most patients eventually need surgery; : Micropeptides restore cardiac function in mice doi: 10.7554/eLife.38319 According to a study by eLife, researchers have found a micropeptide molecule that restores normal heart function in mice. this molecule works by preventing calcium regulation disorders and heart remodeling, and could be a promising target for new gene therapy for heart failure. the most significant damage caused by calcium in many of the processes that cause heart failure. the activity of calcium in and out of the cells can cause the heart muscle to contract and relax. a calcium pump called SERCA controls the flow of calcium, but the molecule's action is impaired in heart failure, and previous studies have suggested that enhancing SERCA's activity can keep the heart constricted and treat heart failure. our lab recently discovered a micropeptide called Dwarf Open Reading Frame (DWORF), which binds directly to SERCA and enhances its activity," explains Catherine Makarewich, a postdoctoral researcher at the University of Texas Southwestern Medical Center. "In this study, we explored the therapeutic potential of high levels of DWORF as a way to increase SERCA activity and improve heart failure cardiac contraction." previous work by the team, DWORF works by replacing molecules that inhibit SERCA, called phosphorus-affected proteins (PLNs). To further study this, they designed mice to have higher levels of DWORF and/or PLN in the heart, and then studied their effects. : Chinese scientists have developed peptide drugs to treat prostate cancer doi: 10.1016/j.ccell.2017.02.017 In a new study published in the international academic journal Cancer Cell, researchers from the University of Michigan have developed a new treatment that can target genetic mutations that occur in about half of prostate cancers. when the genesTMPRS2 and ERG are relocated and fused together on the chromosomes, prostate cancer develops. but developing small molecule inhibitors targeting ERG has been challenging In this study, researchers used macromolecule peptides to target ERG, which they demonstrated in cell lines and animal models that are effective in targeting and promoting the degradation of ERG fusion proteins, with little effect on normal cell function. " targeting the expression of this fusion gene is a big challenge. we solve dissomented from another angle. ", says Arul M. Chinnaiyan, author of the article. researchers have found a group of peptides that can interact specifically with ERG proteins. they tested the group of peptides on cell lines that produce fusion gene products and found that they could disrupt ERG function. in cells that do not produce this fusion gene product, these peptides have little effect on gene expression. they also studied how these peptides affect the biological processes of ERG regulation. !--/ewebeditor:!--webeditor: !--.page title"--10 Metab Engin: New peptide compounds - prominemycin is expected to treat SARS-CoV-2 infection doi: 10.1016/j Researchers have been stepping up efforts to produce a promising drug to effectively kill THE SARS-CoV virus in cell cultures, which may now also be effective against SARS-CoV-2 infection, a close relative of the SARS-CoV virus. , in a recent study published in the international journal Blyperfect, scientists from Northwestern University in the United States and Shanghai University of Science and Technology in China developed a very promising molecule, valinomycin, in a cell-free system, based on a cell-free system, and researchers are expected to increase the production of promycin by more than 5,000 times in just a few rapid design cycles, while achieving a higher molecular concentration than previous cells. researcher Michael Jewet.